Suppression of laser-induced choroidal neovascularization by oral administration of SA3443 in mice

FEBS Letters

Volumn 579, Issue 27, 2005, Pages 6084-6088

  Muranaka, Kimimasa ^a   Yanagi, Yasuo ^a   Tamaki, Yasuhiro ^a   Takahashi, Hidenori ^a   Usui, Tomohiko ^a   Ohashi, Koji ^b   Matsuoka, Hidehito ^b   Senda, Toshihiko ^b  

^a UNIVERSITY OF TOKYO   (Japan)

^b SANTEN PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Choroidal neovascularization; Hypoxia; SA3443; Vascular endothelial growth factor

Indexed keywords

DISULFIDE; HEXAHYDRO 7,7 DIMETHYL 6 OXO 1,2,5 DITHIAZOCINE 4 CARBOXYLIC ACID; MESSENGER RNA; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL HYPOXIA; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; LASER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUBRETINAL NEOVASCULARIZATION;

ADMINISTRATION, ORAL; ANAEROBIOSIS; ANIMALS; AZOCINES; CHOROIDAL NEOVASCULARIZATION; DISULFIDES; EYE; LASERS; MICE; MICE, INBRED C57BL; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

ANIMALIA;

EID: 27544456419     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2005.09.079     Document Type: Article

References (40)

1. F.L. Ferris, S.L. Fine, and L. Hyman Age-related macular degeneration and blindness due to neovascular maculopathy Arch. Ophthalmol. 102 1984 1640 1642
2. T. Ishibashi, Y. Hata, H. Yoshikawa, K. Nakagawa, K. Sueishi, and H. Inomata Expression of vascular endothelial growth factor in experimental choroidal neovascularization Graefes Arch. Clin. Exp. Ophthalmol. 235 1997 159 167
3. W.Y. Shen, M.J. Yu, C.J. Barry, I.J. Constable, and P.E. Rakoczy Expression of cell adhesion molecules and vascular endothelial growth factor in experimental choroidal neovascularisation in the rat Br. J. Ophthalmol. 82 1998 1063 1071
4. N. Kwak, N. Okamoto, J.M. Wood, and P.A. Campochiaro VEGF is major stimulator in model of choroidal neovascularization Invest Ophthalmol. Vis. Sci. 41 2000 3158 3164
5. Y. Yanagi, Y. Tamaki, R. Obata, K. Muranaka, N. Homma, H. Matsuoka, and H. Mano Subconjunctival administration of bucillamine suppresses choroidal neovascularization in rat Invest. Ophthalmol. Vis. Sci. 43 2002 3495 3499
6. Eyetech Study Group Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results Ophthalmology 110 2003 979 986
7. K. Takahashi Topical nepafenac inhibits ocular neovascularization Invest Ophthalmol. Vis. Sci. 44 2003 409 415
8. N. Ishida, K. Nakata, K. Takase, M. Tanaka, and S. Mita The protective effects of SA3443, a novel cyclic disulfide, on chronic liver injuries in rats J. Hepatol. 13 1991 200 207
9. N. Ishida, K. Nakata, M. Tanaka, K. Takase, and S. Mita The protective effects of (4R)-hexahydro-7,7-dimethyl-6-oxo-1,2,5-dithiazocine-4-carboxylic acid (SA3443), a novel cyclic disulfide, on chemically-induced acute liver injury Jpn. J. Pharmacol. 55 1991 275 278
10. S. Ito, A. Ota, H. Suhara, K. Tabashi, and Y. Kawashima Synthesis and pharmacological activities of novel cyclic disulfide and cyclic sulfide derivatives as hepatoprotective agents Chem. Pharm. Bull. (Tokyo) 41 1993 1066 1073
11. K. Nakata, M. Sasano, K. Matsunaga, M. Tanaka, and S. Mita Protective effect of (4R)-hexahydro-7,7-dimethyl-6-oxo-1,2,5-dithiazocine-4-carboxylic acid (SA3443), a novel cyclic disulfide, on immunologically induced liver injuries in mice Arch. Int. Pharmacodyn. Ther. 309 1991 170 184
12. M. Sasano, M. Hayashi, K. Matsunaga, K. Nakata, and S. Mita SA3443, a novel cyclic disulfide compound, depresses anti-SRBC antibody-forming cell responses in the mouse through inhibition of antigen-presenting cell activities Drugs Exp. Clin. Res. 17 1991 337 341
13. M. Sasano, M. Tanaka, K. Nakata, and S. Mita Induction of cytotoxic cell activities by a novel cyclic disulfide compound, SA3443 in vivo Immunopharmacol. Immunotoxicol. 13 1991 121 133
14. M. Sasano, K. Nakata, and S. Mita Inhibitory effect of (4R)-hexahydro-7,7-dimethyl-6-oxo-1,2,5-dithiazocine-4-carboxylic acid (SA3443), a novel cyclic disulfide, on the production of TNF-like factor from Propionibacterium acnes-primed rat liver macrophages/Kupffer cells Jpn. J. Pharmacol. 59 1992 493 496
15. T. Setogawa, H. Kosano, I. Ogihara-Umeda, T. Kayanuma, and H. Nishigori Preventive effect of SA3443, a novel cyclic disulfide, on glucocorticoid-induced cataract formation of developing chick embryo Exp. Eye Res. 58 1994 689 695
16. H. Suda, M. Okamoto, and M. Fukumoto Delayed-type skin allergic reaction in guinea pigs induced by anti-rheumatic compounds with sulfhydryl groups Immunopharmacol. Immunotoxicol. 15 1993 387 396
17. M. Tanaka, K. Nakata, K. Takase, and S. Mita The protective effect of (4R)-hexahydro-7,7-dimethyl-6-oxo-1,2,5-dithiazocine-4-carboxylic acid (SA3443), a novel cyclic disulfide, on acetaminophen-induced liver injury Nippon Yakurigaku Zasshi 97 1991 191 198
18. M. Tanaka, K. Nakata, and S. Mita The inhibitory effect of SA3443, a novel cyclic disulfide compound, on alpha-naphthyl isothiocyanate-induced intrahepatic cholestasis in rats Clin. Exp. Pharmacol. Physiol. 20 1993 543 547
19. F. Tsuji, N. Morikawa, and H. Takashina Different pharmacokinetics of (4R)-hexahydro-7,7-dimethyl-6-oxo-1,2,5-(3-14C)dithiazocine-4-carboxylic acid between the fasting and non-fasting rat: role of intestinal microorganisms Xenobiotica 28 1998 53 62
20. M. Nagashima, K. Wauke, D. Hirano, S. Ishigami, H. Aono, M. Takai, M. Sasano, and S. Yoshino Effects of combinations of anti-rheumatic drugs on the production of vascular endothelial growth factor and basic fibroblast growth factor in cultured synoviocytes and patients with rheumatoid arthritis Rheumatology (Oxford) 39 2000 1255 1262
21. F. Tsuji, H. Matsuoka, H. Aono, M. Takai, M. Horiuchi, K. Nishimura, and S. Mita Effects of sulfhydryl compounds on interleukin-1-induced vascular endothelial growth factor production in human synovial stromal cells Biol. Pharm. Bull. 23 2000 663 665
22. Y. Yanagi, Y. Tamaki, Y. Inoue, R. Obata, K. Muranaka, and N. Homma Subconjunctival doxifluridine administration suppresses rat choroidal neovascularization through activated thymidine phosphorylase Invest. Ophthalmol. Vis. Sci. 44 2003 751 754
23. R. Ideta, Y. Yanagi, Y. Tamaki, F. Tasaka, A. Harada, and K. Kataoka Effective accumulation of polyion complex micelle to experimental choroidal neovascularization in rats FEBS Lett. 557 2004 21 25
24. J.L. Edelman, and M.R. Castro Quantitative image analysis of laser-induced choroidal neovascularization in rat Exp. Eye Res. 71 2000 523 533
25. J. Baffi, G. Byrnes, C.C. Chan, and K.G. Csaky Choroidal neovascularization in the rat induced by adenovirus mediated expression of vascular endothelial growth factor Invest. Ophthalmol. Vis. Sci. 41 2000 3582 3589
26. J.Z. Cui, H. Kimura, C. Spee, G. Thumann, D.R. Hinton, and S.J. Ryan Natural history of choroidal neovascularization induced by vascular endothelial growth factor in the primate Graefes Arch. Clin. Exp. Ophthalmol. 238 2000 326 333
27. X. Yi, N. Ogata, M. Komada, C. Yamamoto, K. Takahashi, K. Omori, and M. Uyama Vascular endothelial growth factor expression in choroidal neovascularization in rats Graefes Arch. Clin. Exp. Ophthalmol. 235 1997 313 319
28. K. Ishida, N. Yoshimura, M. Mandai, and Y. Honda Inhibitory effect of TNP-470 on experimental choroidal neovascularization in a rat model Invest. Ophthalmol. Vis. Sci. 40 1999 1512 1519
29. R.K. Bruick Oxygen sensing in the hypoxic response pathway: regulation of the hypoxia-inducible transcription factor Genes Dev. 17 2003 2614 2623
30. H. Ozaki Hypoxia inducible factor-1alpha is increased in ischemic retina: temporal and spatial correlation with VEGF expression Invest. Ophthalmol. Vis. Sci. 40 1999 182 189
31. N. Pore Sp1 is involved in Akt-mediated induction of VEGF expression through an HIF-1-independent mechanism Mol. Biol. Cell 15 2004 4841 4853
32. J.B. Jonas, I. Kreissig, and R. Degenring Intravitreal triamcinolone acetonide for treatment of intraocular proliferative, exudative, and neovascular diseases Prog. Retin. Eye Res. 24 2005 587 611
33. H. Takahashi, Y. Yanagi, Y. Tamaki, S. Uchida, and K. Muranaka COX-2-selective inhibitor, etodolac, suppresses choroidal neovascularization in a mice model Biochem. Biophys. Res. Commun. 325 2004 461 466
34. T. Papadaki The role of lanreotide in the treatment of choroidal neovascularization secondary to age-related macular degeneration: a pilot clinical trial Retina 23 2003 800 807
35. S. Matsuda, F. Gomi, Y. Oshima, M. Tohyama, and Y. Tano Vascular endothelial growth factor reduced and connective tissue growth factor induced by triamcinolone in ARPE19 cells under oxidative stress Invest. Ophthalmol. Vis. Sci. 46 2005 1062 1068
36. H.E. Grossniklaus Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization Mol. Vis. 8 2002 119 126
37. D.G. Espinosa-Heidmann, I.J. Suner, E.P. Hernandez, D. Monroy, K.G. Csaky, and S.W. Cousins Macrophage depletion diminishes lesion size and severity in experimental choroidal neovascularization Invest. Ophthalmol. Vis. Sci. 44 2003 3586 3592
38. E. Sakurai, A. Anand, B.K. Ambati, N. van Rooijen, and J. Ambati Macrophage depletion inhibits experimental choroidal neovascularization Invest. Ophthalmol. Vis. Sci. 44 2003 3578 3585
39. C. Tsutsumi The critical role of ocular-infiltrating macrophages in the development of choroidal neovascularization J. Leukoc. Biol. 74 2003 25 32
40. P.S. Bora Role of complement and complement membrane attack complex in laser-induced choroidal neovascularization J. Immunol. 174 2005 491 497